It is essential to precisely identify therapy-relevant genetic changes quickly, cost-efficiently and in compliance with all quality standards. With the knowledge of these tumor-specific mutations, diagnoses can be further expanded to identify individual therapy options and drug combinations. Ineffective therapies and their side effects are avoided and new treatment options become available.
“For these clinical requirements we have developed the molecular pathology panel in cooperation with oncologists and pathologists. Also we have incorporated CeGaT’s long-standing expertise in the enrichment of relevant genomic areas. The CeGaT molecular pathology panel covers the most common tumor entities. It is possible to examine technically demanding tumor samples (liquid biopsy, small number of tumor cells, FFPE tissue). At CeGaT, the proportion of tumor samples that cannot be processed due to technical reasons is below 2%. Therefore it is possible for attending oncologists to obtain results quickly and efficiently. The findings support our colleagues in selecting a targeted therapy.” says Dr. med. Dr. rer. nat. Saskia Biskup, CEO of CeGaT.
The CeGaT molecular pathology panel covers the following tumor entities:
- Breast, ovarian and pancreatic carcinomas (10 genes, SSP05): BRCA1 / 2, ATM, CDH1, CHEK2, PTEN, PALB2, RAD51C, RAD51D, TP53
- Melanoma (4 genes, PAT01): BRAF exons 11, 15, V600; NRAS exons 2-4; KIT exons 9, 11, 13, 14, 17, 18; TP53
- Colorectal carcinoma (5 genes, PAT02): BRAF exons 11, 15, V600; KRAS exons 2-4; NRAS exons 2-4, PIK3CA exons 9, 20; TP53
- Lung carcinoma (7 genes, PAT03): BRAF exons 11, 15, V600; EGFR exons 18-21, KRAS exons 2-4; ERBB2: (HER2) exon 20; MET exon 13, PIK3CA exons 9, 20; TP53, ALK-EML4; translocation, ROS1 translocation
- Gastrointestinal stromal tumors (4 genes, PAT04): BRAF exons 11, 15, V600; PDGFRA exons 12, 14, 18; KIT exons 9, 11, 13, 14, 17, 18; TP53
- Glioblastoma (8 genes, PAT05): BRAF exons 11, 15, V600; IDH1 exon 2; IDH2 exon 4; PIK3CA exons 9, 20; TP53; TERT hotspots in the promoter; H3F3A, HIST1H3B
- Microsatellite instability (MSI) via PCR: (markers: BAT25, BAT26, NR21, NR22, NR27)